Alfred Habel, MD
Pulmonary Disease · Kenosha, WINPI 1760439608
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $141,836 of the $194,304 with a category attached, or 73.0%. 32 manufacturers reported payments, led by Mylan Specialty L.p. at 40.3% of the total. Among pulmonary disease clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 723 payments — averaging $268.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$78K
- AstraZeneca$75K
- GSK$20K
- Viatris Specialty LLC$6K
- Sanofi$5K
- Sunovion Pharmaceuticals Inc.$4K
- plus $6K from 26 others
What the payments were for
- Consulting fees$23,81712%
- Speaking & faculty fees$141,83673%
- Travel & lodging$13,9337%
- Food & beverage$14,5017%
- Education$2000%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 177 | $78,208 |
| AstraZeneca | 181 | $74,944 |
| GSK | 94 | $20,166 |
| Viatris Specialty LLC | 15 | $5,987 |
| Sanofi | 35 | $5,253 |
| Sunovion Pharmaceuticals Inc. | 22 | $3,862 |
| Harmony Biosciences LLC | 40 | $2,185 |
| Jazz Pharmaceuticals Inc. | 61 | $1,228 |
| Avadel CNS Pharmaceuticals, LLC | 14 | $465 |
| Insmed, Inc. | 27 | $447 |
| Regeneron Healthcare Solutions, Inc. | 13 | $282 |
| Verona Pharma, Inc. | 6 | $205 |
| Resmed Corp | 3 | $136 |
| Boehringer Ingelheim | 3 | $123 |
| Mallinckrodt Enterprises LLC | 4 | $120 |
| Novartis | 1 | $100 |
| Amgen | 5 | $90 |
| Itamar Medical Inc | 1 | $84 |
| Idorsia Pharmaceuticals US Inc | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $60 |
| Philips North America LLC | 3 | $48 |
| Electromed, Inc. | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Pfizer | 1 | $16 |
| Boston Scientific | 1 | $13 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$194,304 in reported general payments places this provider in the 95th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumryzSodium Oxybate | 17 | $305,737 |
| Fasenra PenBenralizumab | 25 | $149,910 |
| NucalaMepolizumab | 40 | $147,546 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 126 | $96,042 |
| XolairOmalizumab | 26 | $90,279 |
| Breo ElliptaFluticasone/Vilanterol | 143 | $69,092 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $59,573 |
| Dupixent PenDupilumab | 11 | $43,783 |
| SymbicortBudesonide/Formoterol Fumarate | 113 | $39,750 |
| Spiriva HandihalerTiotropium Bromide | 46 | $37,060 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 37 | $27,175 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 110 | $22,189 |
| Advair HfaFluticasone Propion/Salmeterol | 46 | $21,846 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 31 | $11,434 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $10,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avadel CNS Pharmaceuticals, LLCLumryz | $465 | $305,73717 claims |
| GSKNucala, Breo Ellipta, Trelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $20,166 | $292,886283 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $74,944 | $135,792239 claims |
| Boehringer IngelheimCombivent Respimat | $123 | $27,17537 claims |
| MerckDulera, Belsomra | $21 | $13,59834 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $21 | $9,58118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Kenosha
- Hasnain BawaadamKenosha$686K
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Manar Al ShahrouriGreen Bay$61K
- Kurt HuMilwaukee$55K
- Julie BillerMilwaukee$52K
- Mark BarashMilwaukee$52K
- Rahul NanchalMilwaukee$42K
- Steven LehMilwaukee$40K
- Ali MusaniMilwaukee$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.